Mackenzie Financial
CSTL icon

Mackenzie Financial’s Castle Biosciences CSTL Stock Holding History

Mackenzie Financial’s Portfolio CSTL Stock Details CSTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$18.9M Buy
793,507
+719,396
+971% +$16M 0.02% 461
2026
Q1 		$1.82M Buy
74,111
+36,794
+99% +$1.21M ﹤0.01% 946
2025
Q4 		$1.46M Buy
37,317
+13,113
+54% +$423K ﹤0.01% 961
2025
Q3 		$551K Hold
24,204
– – ﹤0.01% 1223
2025
Q2 		$494K Sell
24,204
-3,256
-12% -$60.3K ﹤0.01% 1232
2025
Q1 		$550K Buy
27,460
+6,440
+31% +$159K ﹤0.01% 1168
2024
Q4 		$560K Buy
+21,020
New +$640K ﹤0.01% 1119

Other funds holding CSTL

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Allianz Asset Management
Allianz Asset Management Munich, Germany $123B AUM 45.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
SPPAM
Summit Partners Public Asset Management Boston, Massachusetts $5.69B AUM 259.25% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Mackenzie Financial's CSTL Position: Q2 2026 in Review

Mackenzie Financial increased its Castle Biosciences (CSTL) stake by 971% in Q2 2026, buying an estimated $16M and bringing the position to 793,507 shares worth $18.9M. The position accounts for 0.02% of the portfolio, ranked #461.

Mackenzie Financial first reported a position in CSTL in Q4 2024 and has held it in 7 quarters since. 176 funds tracked by Wall St. Rank hold CSTL as of Q2 2026.

  • Mackenzie Financial held 793,507 shares of Castle Biosciences worth $18.9M as of Q2 2026.
  • Mackenzie Financial bought 719,396 Castle Biosciences shares in Q2 2026, an estimated $16M.
  • Castle Biosciences made up 0.02% of Mackenzie Financial's portfolio in Q2 2026, its #461 holding.
  • Mackenzie Financial first reported a position in Castle Biosciences in Q4 2024 and has held it in 7 quarters since.
  • 176 funds tracked by Wall St. Rank held Castle Biosciences as of Q2 2026.

Based on Mackenzie Financial's 13F filing for Q2 2026, filed 13 Aug 2026.